To "Grow" or "Go": TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN

Daniel J. Shiwarski1,2,3, Chunbo Shao4, Anke Bill5, Jean Kim1,2, Dong Xiao1,2, Carol A. Bertrand6, Raja S. Seethala7, Daisuke Sano8, Jeffery N. Myers9, Patrick Ha4, Jennifer Grandis1,2, L. Alex Gaither5, Manojkumar A. Puthenveedu3, and Umamaheswar Duvvuri1,2

Abstract

Purpose: Tumor metastasis is the leading cause of death in patients with cancer. However, the mechanisms that underlie metastatic progression remain unclear. We examined TMEM16A (ANO1) expression as a key factor shifting tumors between growth and metastasis.

Experimental Design: We evaluated 26 pairs of primary and metastatic lymph node (LN) tissue from patients with squamous cell carcinoma of the head and neck (SCCHN) for differential expression of TMEM16A. In addition, we identified mechanisms by which TMEM16A expression influences tumor cell motility via proteomic screens of cell lines and in vivo mouse studies of metastasis.

Results: Compared with primary tumors, TMEM16A expression decreases in metastatic LNs of patients with SCCHN. Stable reduction of TMEM16A expression enhances cell motility and increases metastases while decreasing tumor proliferation in an orthotopic mouse model. Evaluation of human tumor tissues suggests an epigenetic mechanism for decreasing TMEM16A expression through promoter methylation that correlated with a transition between an epithelial and a mesenchymal phenotype. These effects of TMEM16A expression on tumor cell size and epithelial-to-mesenchymal transition (EMT) required the amino acid residue serine 970 (S970); however, mutation of S970 to alanine does not disrupt the proliferative advantages of TMEM16A overexpression. Furthermore, S970 mediates the association of TMEM16A with Radixin, an actin-scaffolding protein implicated in EMT.

Conclusions: Together, our results identify TMEM16A, an eight transmembrane domain Ca2+-activated Cl−/C0 channel, as a primary driver of the "Grow" or "Go" model for cancer progression, in which TMEM16A expression acts to balance tumor proliferation and metastasis via its promoter methylation.

Introduc­tion

One of the main predictors of survival for patients with squamous cell carcinoma of the head and neck (SCCHN) is the presence of nodal metastases; however, little is understood about the mechanisms that underlie its development (1). Patients with SCCHN often suffer from locally advanced disease and inevitable recurrence despite aggressive treatments. Any additional insight into the driving force behind tumor progression toward metastasis would be translationally and scientifically beneficial for all patients with advanced disease.

Generally, tumor progression requires both tumor growth and subsequent metastatic development. The cellular events driving this progression require complex coordinated regulation of both growth and motility pathways. These complementary pathways exist in a balance, whereby tumor cells can oscillate between states through precise molecular alterations. Gil-Hen and colleagues have reported that tumor cells have the ability to manipulate intracellular signaling pathways to independently induce tumor growth while diminishing metastasis (2).

Here, we implicate TMEM16A as a critical factor that can independently shift tumors between the growth and metastatic states. TMEM16A is an eight transmembrane domain Ca2+-activated chloride channel (3). It is localized to
The 11q13 chromosomal amplicon, and is frequently overexpressed in many solid malignancies including breast cancer, bladder cancer, and SCCHN (4, 5). We have recently reported that when TMEM16A is overexpressed in primary SCCHN it directly contributes to tumor proliferation via activation of the RAS–RAF–ERK–CCND1 pathway and correlates with decreased patient survival (6). The role of TMEM16A expression in metastasis setting has not been tested. In addition, the molecular mechanisms underlying potential contributions of TMEM16A expression on cell motility and metastasis remain unknown. Our goal was to conclusively determine the direct effects of stable TMEM16A expression on tumor progression toward metastasis in vivo.

Specifically, our results indicate that increasing TMEM16A expression promotes primary tumor growth and decreases motility, whereas decreased expression slows proliferation allowing for metastatic progression. We show that TMEM16A expression is downregulated in metastatic lymph nodes (LN) when compared with paired primary SCCHN tumors from human patients. Using both in vitro and in vivo systems, we demonstrate that TMEM16A, through its S970 amino acid, directly influences tumor cell motility and metastases by affecting epithelial-to-mesenchymal transition (EMT) and expression of cytoskeletal and adhesion molecules, independently of its growth characteristics. Furthermore, S970 is required for the interaction between TMEM16A and the actin-scaffolding protein Radixin. In addition, in vivo expression of TMEM16A is controlled by promoter methylation, a novel mechanism by which TMEM16A gene expression is regulated. These data identify TMEM16A promoter hypermethylation as a key driving factor for the transition of tumor cells between proliferative and metastatic states, a central idea in the transformative "Grow" or "Go" model for tumor progression.
final area of the wound 24 hours later using ImageJ software. This calculation of the difference between the initial and final areas allowed for a consistent measurement of movement regardless of inconsistencies in the wound itself.

**E-cadherin luciferase assay**

E-cadherin promoter activity assay was performed as previously reported (7). An E-cadherin luciferase reporter construct and Renilla control plasmid were transfected using Lipofectamine 2000 into T24 cancer cells. The luciferase activity was evaluated 24 hours after the transfection using the Promega Dual Luciferase Kit. The samples were read using a luminometer according to the Promega protocol, and the amount of individual florescence was normalized to the amount of Renilla luciferase and total protein concentration for each sample.

**Densitometry**

Densitometry from digital scans of X-ray film after immunoblotting was performed using ImageJ software and quantification via the LI-COR Odyssey Imaging system when applicable.

**Primary tissue samples**

Paired primary and metastatic tissues were collected after obtaining informed consent and approval from the University of Pittsburgh Institutional Review Board. Tissue samples were formalin-fixed and paraffin-embedded from patients who underwent curative surgery for SCCHN at our institution. Staining was performed with anti-TMEM16A antiserum (clone SP31; Thermo Fisher). Slides were scored using a semi-quantitative system.

**Cell size measurements**

T24 cancer cells were plated onto 35-mm MatTek dishes at 50% confluence. The cells were imaged with a ×40 objective and borders were drawn to measure the cell size as total area. Area was measured in square micrometers. In addition, flow cytometry was performed by plotting forward scatter compared with side scatter to establish a comparative cell size for the T24 control, TMEM16A overexpression, scrambled shRNA control, and TMEM16A shRNA cell lines.

**Bisulfite treatment and quantitative methylation-specific PCR**

The EpiTect Bisulfite Kit (Qiagen) was used to convert unmethylated cytosines in DNA to uracil according to the manufacturer's instructions. Quantitative methylation-specific PCR (qMSP) was carried out in a 7900 sequence detector (PerkinElmer Applied Biosystems) and analyzed by a sequence detector system (SDS 2.3; Applied Biosystems), as previously described (8). The TMEM16A qMSP primer sequences designed were: forward 5'-AGGATCGTTTATATTAC-3' and reverse 5'-CGCGACCCTCCCGCC-3'. The TMEM16A qMSP probe sequence was 6FAM 5'-CGCACCACCGGTACCCTCG-3' TAMRA. The primers and probe sequences for β-actin (an internal reference standard) and detailed qMSP conditions are described by Shao and colleagues (8).

Leukocyte DNA from a healthy individual was methylated in vitro with excess SssI methyltransferase (New England Biolabs, Inc.) to generate completely methylated DNA. Serial dilutions (30–0.003 ng) of this bisulfite-treated methylated DNA were used to construct a calibration curve. All data points were within the range of sensitivity and reproducibility of the assay based on the calibration curve. The methylation levels in each sample were determined as a ratio of qMSP-amplified gene to β-actin (reference gene) and then multiplied by 1,000 for easier tabulation (average value of gene triplicates divided by the average value of β-actin triplicates × 1,000).

**Mouse xenografts**

Implantation of tumor cells into the lateral tongues of nude mice generated orthotopic tumor xenografts. When tumors reached a critical size (or after 2 weeks), mice were sacrificed and tissues were harvested for histology. LN metastases were determined by H&E staining of cervical LNs.

**Global proteomic analysis**

T24 cells were stably transduced with viral constructs encoding scrambled control or TMEM16A shRNA lentiviral particles. Stabled pooled clones overexpressing TMEM16A or control plasmids were also generated. Cell pellets were harvested and lysed. Mass spectrometry methods were used to evaluate global expression changes (9, 10). These data were then used to generate global protein expression changes in an unbiased fashion. Proteins that changed in a predictable fashion with TMEM16A manipulation (i.e., increased with TMEM16A overexpression and subsequently decreased with TMEM16A knockdown, or vice versa) were identified. This subset of proteins was then subjected to INGENTUITY analysis to identify cellular pathways that were affected with TMEM16A manipulation.

**Cell viability assay**

For proliferation and viability analysis, cells were plated in black-walled 96-well optical plates at 5 × 10^3 cells per well. The CellTiter-Glo Assay (Promega) was used according to the manufacturer's directions to establish proliferation viability for multiple cell lines and experimental conditions.

**Quantitative reverse transcription PCR**

TaqMan primers and probes were designed with the PRIMER EXPRESS V.2.0.0 program (Applied Biosystems). Reverse transcription was carried out as described previously (4, 6, 11). Quantitative reverse transcription PCR (qRT-PCR) was performed for TMEM16A and GAPDH (used as an endogenous control). For E-cadherin and Snail mRNA evaluation, the primers and PCR conditions were chosen from Rosivatz and colleagues (12). All probes and primer were purchased from IDT DNA Technologies as probe and primer mixes.
Statistical analysis

Statistical analysis was performed using GraphPad Prism 4 or Stat Exact software. All data are reported as mean ± SEM unless stated otherwise. A paired t-test was used to evaluate differences in TMEM16A expression between paired primary and metastatic tumor tissue.

All experiments performed in mice were conducted after obtaining informed consent and approval from the University of Pittsburgh Institutional Animal Care and Use Committee. All human tissues were acquired after obtaining informed consent under Institutional Review Board approval.

Results

TMEM16A expression is decreased in metastatic nodal tissue

We previously demonstrated that TMEM16A expression is increased in primary SCCCHN tumors (6). Recent reports have suggested that TMEM16A overexpression might play a role in tumor cell motility (13). We therefore sought to determine whether TMEM16A expression in patients with SCCCHN varies between metastatic LN compared with paired primary tumors. We evaluated TMEM16A expression via immunohistochemistry in 21 SCCCHN primary tumor/metastatic LN pairs. TMEM16A primary tumor expression was higher compared with paired metastatic tissue for 18 of 21 patients; in the remaining 3 patients, the expression was comparable. A representative example of three paired primary and metastatic nodal tissue samples is shown in Fig. 1A. A semi-quantitative scoring of the IHC staining demonstrated approximately 50% decrease in TMEM16A expression levels in the metastatic tissue normalized to paired primary tissue (Fig. 1B).

Interestingly, TMEM16A expression in the primary tumor did not correlate with the development of nodal metastases (Supplementary Fig. S1).

To determine whether differences in TMEM16A expression between the primary tumor and metastatic nodal tissue were due to changes within the tumor cells themselves or an effect contributed by the surrounding stromal tissue, we decided to use immortalized cell lines isolated from either primary or metastatic nodal tissue, and evaluate them for TMEM16A expression. RNA was isolated from SCCHN cell lines derived from syngeneic paired primary and LN metastatic tissue (UPCI-4A/B and UM-SCC10A/B), and analyzed for differences in TMEM16A mRNA levels. TMEM16A mRNA expression was significantly decreased in metastases-derived cell lines compared with their paired-primary line (Fig. 1C). To determine whether expression of TMEM16A was actively downregulated during the formation of nodal metastases, we implanted SCCHN cell lines known to have endogenous expression of TMEM16A and to form spontaneous metastasis, FaDu and HN5, into the tongue of nude mice. After sufficient tumor growth, the primary tumors and any nodal metastatic tissues found were harvested and evaluated for TMEM16A protein expression. In both FaDu and HN5 tumors, the nodal metastatic tissue exhibited decreased TMEM16A expression compared with the primary tumor site (Fig. 1D). The changes in expression during metastatic formation in these ectopic models suggest that TMEM16A changes expression throughout tumor progression toward nodal metastasis. Primary tumors exhibit high expression of TMEM16A, whereas expression in nodal metastases is diminished. This suggests a mechanism in which tumor cells with high TMEM16A expression can dynamically downregulate gene expression to facilitate the formation of nodal metastasis.

TMEM16A downregulation promotes cell migration and increases nodal metastases

Given our prior data (Fig. 1A–D), we hypothesized that a reduction in TMEM16A promotes the ability of tumor cells to establish nodal metastases. A fundamental trait a tumor cell must acquire to successfully metastasize is the ability to increase cell motility and migration. We therefore evaluated TMEM16A’s influence on these metastatic phenotypes using a wound-closure assay and Transwell migration chambers, respectively. To evaluate these characteristics independent of TMEM16A expression on tumor cell proliferation, we constructed stable knockdowns of TMEM16A with lentiviral shRNA, and performed wound-closure and migration assays within a time period less than the cell lines doubling rate. UM-SCC1 tumor cells, an SCCHN-derived cell line harboring the 11q13 amplification, were stably transduced with TMEM16A shRNA, and knockdown was confirmed via immunoblotting (Fig. 2A). The stable TMEM16A knockdown led to approximately 60% increase in motility when compared with scrambled shRNA control cells as assessed by wound-closure assays (Fig. 2A and B). In addition, Transwell migration assays performed with the same stable cell line revealed a 2-fold increase in migration for TMEM16A shRNA cells compared with control (Fig. 2C).

To next determine the effects of TMEM16A knockdown in nonamplified cells, we evaluated motility and migration in T24 cancer cells, which lack 11q13 amplification. Similarl, stable knockdown of T24 cancer cells with TMEM16A shRNA demonstrated an increase in both motility assessed by wound-closure and Transwell migration compared with scrambled shRNA control cells (Supplementary Fig. S2).

Together, these results show that stable reduction of TMEM16A expression increases tumor cell motility and migration in vitro independent of 11q13 amplification status.

To determine whether TMEM16A knockdown was sufficient to promote nodal metastases in a previously established SCCHN orthotopic mouse model, we implanted UM-SCC1 cells with stable TMEM16A shRNA knockdown in the floor of mouths of nude mice (12). In agreement with our previous work, UM-SCC1 TMEM16A-shRNA tumors demonstrated a decreased end tumor weight consistent with their reported decreased proliferation ability (ref. 6; Fig. 2D). Despite their reduced size, UM-SCC1 TMEM16A-shRNA tumors formed 3-fold more metastatic nodules when compared with scrambled shRNA-derived tumors (Fig. 2E). These in vitro and in vivo results suggest that decreased expression of TMEM16A is sufficient to promote
metastatic capabilities of SCCHN cells independent of tumor proliferation.

**TMEM16A overexpression decreases cell migration and invasion**

In UM-SCC1 and T24 cancer cells, knockdown of TMEM16A expression promoted metastatic capabilities through increased motility, migration, and nodal metastasis formation. To next determine the effects of TMEM16A overexpression on cancer cell motility and migration, we focused on T24 cancer cells because of their moderate basal TMEM16A expression, and lack of 11q13 amplification. Immunoblotting confirmed stable overexpression of TMEM16A in T24 cell line clones (Supplementary Fig. S3A). In these cells, TMEM16A stable overexpression, which was previously shown to promote tumor proliferation (6), was associated with a significant reduction of migration (Supplementary Fig. S3A and S3B). This decrease in the migratory capability of TMEM16A-overexpressing cells was recapitulated in our Transwell migration assays (Supplementary Fig. S3C). Similar data showing reduced motility were obtained with UM-SCC1 cells overexpressing TMEM16A (Supplementary Fig. S3E–S3G).

To verify the specificity of TMEM16A overexpression and eliminate the possibilities of nonspecific effects from protein overexpression, the TMEM16A-overexpressing cell line was transduced with TMEM16A lentiviral shRNA to revert the phenotype caused by the overexpression. In our previous article, we demonstrated that when the overexpressing cell line was stably transduced with TMEM16A lentiviral shRNA, the increase in proliferation gained from the TMEM16A overexpression is eliminated (6). To now
investigate migration and invasion, we used Matrigel containing Transwell chambers to evaluate cell invasion through a substrate. The reduction in invasive migration conferred by TMEM16A overexpression was abrogated following infection with shRNA targeting TMEM16A (Supplementary Fig. S3D). These data support the conclusion that increasing TMEM16A confers a decrease in tumor cell motility, migration, and invasion opposite its pro-proliferative effects.

**Overexpression of TMEM16A promotes an epithelial morphology and increased cell size**

Our data (Supplementary Fig. S3) show that TMEM16A overexpression reduces the metastatic characteristics of cancer cells. Therefore, we hypothesized that increasing TMEM16A expression altered cell morphology in a way that would structurally discourage motility and invasion. We again elected to use the T24 cancer cell line to assess the effects of TMEM16A expression on cell morphology. These

---

**Figure 2.** Knockdown of TMEM16A in SCCHN decreases motility and increases propensity for nodal metastasis. A, immunoblotting was performed to confirm the effective knockdown of TMEM16A for these stably expressing cell lines. Wound-healing assays demonstrated an increase in motility for TMEM16A shRNA-expressing SCC1 cells compared with the scrambled shRNA control. Quantification for the change in wound healing via a difference in total area of migration resulted in approximately a 65% increase for TMEM16A shRNA SCC1 cells (mean ± SEM; ††, P < 0.01; n = 3). B, example images are shown of the differences observed in these assays. The white dashed line outlines the area measured for each image. C, to further evaluate the migratory ability of cells with reduced TMEM16A expression, Transwell migration assays were performed. A significant increase in Transwell migration upon knockdown of TMEM16A was observed (mean ± SEM; ††, P < 0.01; n = 3). Representative fields for the Transwell migration assays used in the quantification are depicted (right). D, finally, TMEM16A shRNA and scrambled control SCC1 cells were implanted into the floor of mouth mouse model to evaluate their ability to form LN metastatic nodules. The end primary tumor weights were measured to demonstrate the previously reported reduced growth characteristics of TMEM16A shRNA cells (mean ± SEM; †, P < 0.01; n = 8). E, upon termination of the experiment, mice implanted with TMEM16A shRNA-expressing cells had approximately three times the amount of measurable metastatic nodules relative to the scrambled shRNA control cells implanted in mice (mean ± SEM; †, P < 0.05; n = 8).
cells exhibited prometastatic mesenchymal characteristics at baseline, and appeared to undergo a mesenchymal-to-epithelial transition (MET; refs. 14, 15) upon overexpression of TMEM16A. Stable overexpression of TMEM16A substantially changed the visible cell morphology, inducing an epithelial phenotype characterized by rounded colonial growth that is often inversely correlated with metastasis. T24 cells expressing a stable shRNA knockdown of TMEM16A had a visible mesenchymal appearance similar to the control cells (Fig. 3A).

Another characteristic of a transition from a metastatic competent mesenchymal cell to an epithelial cell is a change in cell size. Decreased cell size is known to correlate with a mesenchymal cell morphology to facilitating migration, whereas increased cell size correlates with a transition to an epithelial cell morphology and a less motile phenotype (16). In our T24 stable overexpressing and knockdown cell lines, we evaluated individual cell area in square micrometers and cell volume as assessed by flow cytometry to quantitate any induced changes in cell size. TMEM16A overexpression resulted in a 68% increase in cell area compared with control, whereas the TMEM16A shRNA knockdown cells demonstrated a 35% reduction in cell area compared with scrambled shRNA (Fig. 3B). In these same T24 cell lines, TMEM16A overexpression led to a significant increase in cell volume as assessed by shifted forward scatter values, and the TMEM16A shRNA knockdown demonstrated a significant decrease in cell volume (Supplementary Fig. S4A and S4B). Representative results from the flow cytometry experiments depict this shift in forward scatter for the overexpression and knockdown cell lines. These data, taken together, illustrate the influence of TMEM16A expression on the regulation of cell size and morphology independent from its influence on cell proliferation, but also suggest a possible mechanism by which changes in cell morphology could either promote or inhibit cell movement and metastatic characteristics by physically altering the rigidity of the cells.

**TMEM16A expression promotes an epithelial phenotype and alters transcriptional regulation of E-cadherin**

During tumor progression toward metastasis, it is known that cell morphology and the actin cytoskeleton are altered through changes in expression of the epithelial protein E-cadherin and the mesenchymal protein vimentin (17, 18). The classical EMT is characterized by a decrease in E-cadherin and an increase in vimentin expression, and is a hallmark of metastatic progression (19). Our data demonstrate that increasing TMEM16A expression increases cell size, decreases motility, migration, and invasion, and can visibly induce an epithelial morphology *in vitro*. These observations, taken together, are indicative of epithelial cell morphology and are predicted to coincide with an increase in E-cadherin and reduction of vimentin expression.

To determine the impact of TMEM16A expression on the regulation of E-cadherin expression, we first assessed *E-cadherin* promoter activity. Using T24 TMEM16A stable overexpression cell line, we observed a 4-fold increase in *E-cadherin* promoter activity when compared with the vector control (Fig. 3C, top). Furthermore, T24 TMEM16A shRNA stable knockdown cells exhibited an 85% decrease in *E-cadherin* promoter activity when compared with scrambled shRNA control (Fig. 3C, bottom).

To conclusively determine whether the effects of TMEM16A on E-cadherin were specific to changes in TMEM16A expression, we performed a rescue experiment. In T24 cells stably expressing TMEM16A shRNA, we rescued stable knockdown with shRNA-insensitive cDNA (TMEM16A'). Quantification of the rescue effect was evaluated via qRT-PCR for TMEM16A mRNA (Supplementary Fig. S5A). We further confirmed that the inhibition of cell proliferation caused by the TMEM16A shRNA was reverted upon coexpression of the TMEM16A' cDNA (Supplementary Fig. S5B). E-cadherin mRNA levels were quantified via qRT-PCR for T24 shRNA knockdown and subsequent rescue cell lines. The cells transduced with the shRNA lentivirus had a 40% reduction in E-cadherin mRNA, which was rescued by expression of TMEM16A' cDNA (Fig. 3D). To corroborate these changes in E-cadherin, the mRNA expression of the E-cadherin transcriptional repressor Snail was also evaluated via qRT-PCR for the same cell lines. Snail mRNA expression increased more than 2-fold upon TMEM16A knockdown, and returned to control levels when transfected with the TMEM16A' cDNA (Fig. 3E). Taken together, these results suggest that altering TMEM16A expression is sufficient to modulate the transcriptional activity and expression of E-cadherin, thus stimulating epithelial cell characteristics.

To further assess a shift from a mesenchymal protein profile in native T24 cancer cells toward an epithelial protein profile immunoblotting was performed on several common prominent candidates for evaluating MET. Upon TMEM16A overexpression, the protein expression of epithelial markers E-cadherin and ZO-1 increased, whereas the mesenchymal proteins vimentin, fibronectin, and α-smooth muscle actin decreased (Fig. 3F). This observed shift in the T24 cell line protein profile confirms a MET upon TMEM16A overexpression, and suggests TMEM16A as a driver of tumor cell morphology.

**Unbiased proteomics analysis reveals a broad range of motility and morphology associated proteins affected by altered TMEM16A expression**

We have shown that modulating TMEM16A expression has a significant effect on the overall metastatic capabilities of UM-SCC1 and T24 tumor cells through regulation of EMT; however, the global impact of altering TMEM16A expression and its influence on proteins associated with cytoskeletal rearrangements necessary to allow EMT and metastasis to occur are unknown. To elucidate the possible molecular pathways underlying the connection between TMEM16A expression and tumor cell metastasis, we used a quantitative-unbiased mass spectroscopy method to determine the overall changes in protein expression profiles in T24 TMEM16A stable overexpression and knockdown cell lines. Positive hits were defined as differentially...
expressed proteins that were altered reciprocally for TMEM16A overexpression and knockdown cells in a consistent and reproducible manner. Using a bioinformatic approach, we noted that of the proteins identified to change most significantly with TMEM16A expression modulation, two prominent categorical distinctions were in the regulation of cellular motility and cytoskeletal regulation.

In total, 27 proteins associated with cell motility or morphology were identified to be differentially regulated between the T24 TMEM16A overexpression and shRNA knockdown cell lines. To highlight the differential expression pattern between the proteins identified, a heatmap of the average peptide counts from the quantitative-unbiased mass spectroscopy runs was constructed for the TMEM16A overexpression and TMEM16A shRNA cells normalized to the vector control or scrambled shRNA control cell lines expression (Fig. 4A). The log2 ratio peptide count between the overexpression and vector control or shRNA knockdown and scrambled shRNA control is represented as a range in color from red (high) to green (low) values. A table depicting the protein gene IDs and log2 ratios compared with controls can be found in Supplementary Table S1.

To construct an interaction map for the proteins identified in this analysis, we conducted an Ingenuity Pathway Analysis for the motility-related protein expression data of the T24 TMEM16A-overexpressing cells compared with their control cells (Fig. 4B). Notably, several of the proteins influenced by TMEM16A manipulation were related to the actin cytoskeleton and are known to be involved in cell motility. In particular, Annexin A2, Filamin A, and Radixin were revealed as pathway nodes and are known to influence cell motility as well as EMT (20, 21). TMEM16A has also been shown to associate with the Ezrin–Radixin–Moesin (ERM) family of proteins, which could act as a link between our observed effects on cell motility and morphology by facilitating an interaction with the actin cytoskeleton (22). Therefore, we focused our further investigations on these candidate proteins.

To validate the data obtained from this global analysis, we choose Annexin A2, Filamin A, and Radixin to examine via immunoblotting. Immunoblotting results confirmed a decrease in Annexin A2 and Filamin A expression in T24 TMEM16A-overexpressing cells, whereas Radixin expression was increased compared with control (Fig. 4C). Densitometry was performed for each protein (n = 3) to allow for a quantified comparison with the mass spectroscopy data (Fig. 4D). These results suggest the possibility that TMEM16A can regulate EMT through interactions with the actin cytoskeleton to promote an epithelial phenotype.

**TMEM16A S970 interacts directly with Radixin and is required for TMEM16A’s effects on cell morphology and EMT**

From our proteomic analysis, the actin-associated protein Radixin seemed to be a good candidate for a mechanism by which TMEM16A could modulate the actin cytoskeleton stability to influence cell morphology and metastasis. Radixin, in cooperation with Ezrin and Moesin, is known to drive and stabilize the association between actin and the plasma membrane. Therefore, we hypothesized that TMEM16A’s effects on cell morphology and EMT could be dependent upon a direct protein–protein interaction to Radixin that would sequester it away from its actin interactions. A comparative evaluation of the TMEM16A amino acid sequence to known ERM binding sites revealed a possible ERM binding domain coordinated around serine 970 within TMEM16A’s cytoplasmic tail. To determine whether TMEM16A S970 is required for TMEM16A’s interaction with Radixin, we mutated the S970 to an alanine (S970A) and performed an immunoprecipitation between TMEM16A and HA-tagged Radixin in HEK-293T cells. Wild-type TMEM16A was found to directly interact with Radixin in HEK-293T cells via our immunoprecipitation experiment, exemplified by a prominent band of approximately 80 kDa (Fig. 5A). When performed with the mutated TMEM16A S970A construct, no apparent band for Radixin was observed after immunoprecipitating for TMEM16A and blotting for Radixin in HEK-293 T cells (Fig. 5A). This immunoprecipitation was repeated three times and quantified via densitometry. A significant increase in the interaction between TMEM16A and Radixin was observed; however, upon mutation of the S970 to an alanine, the association was lost (Fig. 5B).

We next wanted to determine whether the TMEM16A S970 residue is required for the effects contributed by TMEM16A expression on cell morphology and EMT. Stable expression of TMEM16A S970A in T24 cells was generated in pooled clones after transfection. The expression of TMEM16A S970A did not induce an increase in the overall cell size normally associated with TMEM16A overexpression as assed by flow cytometry (Fig. 5C). In addition, overexpression of TMEM16A S970A did not promote an increase in the expression of E-cadherin and a decrease in vimentin expression as evidenced by immunoblotting (Fig. 5D).

To further confirm that expression of the TMEM16A S970A

---

**Figure 3.** TMEM16A expression influences cell morphology and promotes an epithelial protein profile. A, bright field images of T24 cancer cells show a transition from a mesenchymal morphology in control (Ct) or TMEM16A shRNA cells to an epithelial morphology upon TMEM16A overexpression (OE). B, TMEM16A overexpression increased the overall cell area, whereas TMEM16A shRNA decreased cell area (mean ± SEM; *P < 0.001). C, overexpression of TMEM16A was found to directly increase the E-cadherin promoter activity (top), whereas TMEM16A shRNA decreased the E-cadherin promoter activity (bottom; mean ± SEM, n = 3; **, P < 0.001). D and E, the E-cadherin promoter activity assays were supported by the ability of shRNA-resistant TMEM16A-cDNA to rescue the E-cadherin mRNA expression and inversely modulate the transcriptional repressor of E-cadherin, Snail (mean ± SEM; n = 3; **, P < 0.05; ***, P < 0.01; ****, P < 0.001). F, epithelial and mesenchymal markers were evaluated in the presence and absence of TMEM16A overexpression. Increased expression of TMEM16A caused increases in epithelial markers E-cadherin and ZO-1, and resulted in decreased protein expression for mesenchymal markers vimentin, fibronectin, and α-smooth muscle actin (SMA).
did not induce E-cadherin transcription, we evaluated the E-cadherin promoter activity and mRNA expression. Overexpression of TMEM16A S970A has no significant effect on increasing E-cadherin promoter activity or mRNA expression, as well as no effect on the transcriptional repressor for E-cadherin, Snail (Fig. 5E–G). Finally, if TMEM16A S970 is
Figure 5. TMEM16A S970 interacts directly with Radixin and is required for TMEM16A’s effects on cell morphology and EMT. A, immunoprecipitation of TMEM16A from HEK 293 total cell lysate followed by immunoblotting of Radixin demonstrates an interaction between TMEM16A and Radixin (80-kDa band) that is prevented by mutation of the S970 amino acid to alanine. B, quantification of the immunoprecipitation reveals a 3-fold increase in the association between TMEM16A and Radixin that is absent with expression of TMEM16A S970A (mean ± SEM; n = 3; *, P < 0.05). C, overexpression of TMEM16A S970A does not increase the overall cell size as assessed by FSC-H scatter. An example of the traces obtained during flow analysis is shown. ***; P < 0.001. D, immunoblotting reveals no change in the epithelial and mesenchymal markers E-cadherin and vimentin upon overexpression of TMEM16A S970A. E, overexpression of TMEM16A S970A does not induce the E-cadherin promoter activity (mean ± SEM; n = 3; *, P < 0.05). F, overexpression of TMEM16A S970A does not decrease the expression of the Snail, the transcriptional repressor of E-cadherin (mean ± SEM; n = 3; *, P < 0.05). G, overexpression of TMEM16A S970A does not increase the expression of the epithelial marker E-cadherin (mean ± SEM; n = 3; ***, P < 0.001).
Figure 6. Expression of TMEM16A between the primary tumor to LN metastatic nodal tissue is modulated through promoter methylation. A, the TMEM16A genomic DNA sequence plus the 500-bp upstream region were used to determine the location of the TMEM16A CpG island. The TSS is at position nt 0, and the CpG island from nt −100 to +750. qMSP primers and probe were designed against the bisulfite-modified version of ANO1 genomic DNA, and the analyzed region covers from nt +342 to +442. B and C, reduction in promoter methylation with 5-Aza dC/TSA decreased the TMEM16A promoter methylation in tumor cell lines, and subsequently increased the TMEM16A mRNA expression (mean ± SEM; n = 3; **, P < 0.01). Paired primary and nodal metastatic tissue (LN Met) was obtained from patients with SCCN to assess TMEM16A promoter methylation status and mRNA expression. (Continued on the following page.)
required to promote an epithelial phenotype, we next asked whether the increased expression of TMEM16A S970A would promote an increase in tumor cell proliferation independent from its ability to influence EMT. We performed a cell proliferation assay using CellTiter-Glo from Promega to determine the rate of cell proliferation after 3 days of growth in either normal adherent growth conditions or anchorage-independent growth conditions using poly-Hema. In both anchorage-independent and attached growth conditions, stable overexpression of TMEM16A and TMEM16A S970A exhibited a 3- to 4-fold increase in proliferation (Supplementary Fig. S6). Taken together, these data demonstrate that the S970 residue of TMEM16A is required for its association with Radixin, and that this residue is required for the effects on cell morphology and epithelial characteristics associated with increased TMEM16A expression, but does not inhibit its ability to promote cell proliferation.

Expression of TMEM16A in SCCHN patients is mediated via promoter methylation and correlates with epithelial biomarkers

Because TMEM16A expression is reduced in tissues derived from metastatic nodes compared with primary tumor tissue (Fig. 1), we sought to elucidate the mechanism of TMEM16A downregulation in vitro. We hypothesized that TMEM16A is transcriptionally repressed via promoter methylation during metastatic progression. Promoter methylation occurs at regions within the genome where there are high concentrations of CpG dyads (cytosines and guanines linked by a phosphodiester bonds) termed CpG islands. For TMEM16A, we identified a large CpG island spanning a portion of the promoter region from nucleotide (nt) −100 to +750 region relative to the transcription starting site (TSS) of TMEM16A. We designed primers and a probe against the bisulfite-modified version of the TMEM16A CpG island DNA to analyze the region from nt +342 to +442 to quantitatively assess methylation (Fig. 6A). To determine whether the TMEM16A promoter region was able to undergo changes in its methylation status, 5-aza-2'-deoxycytidine (5-Aza dC) and trichostatin A (TSA) treatments were used to un-methylate the DNA, and the percentage of 5-Aza dC-induced demethylation was confirmed by comparing with its normal counterparts (Fig. 6B). Expression of TMEM16A mRNA was significantly (P < 0.01) upregulated after promoter demethylation (Fig. 6C). These results demonstrate that promoter methylation can modulate the expression of TMEM16A in cancer cells.

To test our hypothesis that promoter hypermethylation modulates TMEM16A expression in metastatic nodal tissue, we obtained five paired primary tumor and nodal metastatic tissue samples from patients with SCCHN. For each paired sample, we quantified the amount of TMEM16A promoter methylation and subsequent mRNA expression. Methylation of the TMEM16A promoter region was increased in the metastatic LN tissue (n = 5; Fig. 6D). In addition, all samples demonstrated a concordant decrease in TMEM16A mRNA in the metastatic tissue (Fig. 6E). Furthermore, we wanted to confirm that in these paired samples the tumor protein expression profiles were undergoing an EMT transition in the metastatic nodal tissue. Snail mRNA was increased in four of five metastatic LNs when compared with paired primary tumor (Fig. 6F). This change correlated with a decrease in the E-cadherin mRNA (Fig. 6G) and an increase in the vimentin mRNA, validating our in vitro data in patient samples (Fig. 6H).

Our results, taken together, provide substantial evidence that DNA methylation of TMEM16A’s promoter region is directly regulating TMEM16A expression to drive changes in cell motility, migration, and morphology to promote the progression from primary tumor to metastatic nodal formation. This pleiotropic expression of TMEM16A between the primary and nodal tissue correlates with a transition from an epithelial to a mesenchymal phenotype to promote migratory and invasive capabilities of tumor cells. Finally, this process of transition is dependent upon the S970 residue in the cytoplasmic tail of TMEM16A, which is required for binding to Radixin. A model depicting the conclusions from our data shows the general mechanism by which TMEM16A promotes or inhibits tumor cell motility (Fig. 6I). We have proposed a model in which increased TMEM16A expression promotes tumor cell growth and an epithelial morphology, whereas decreased expression allows for the formation of nodal metastasis from an EMT (Supplementary Fig. S7).

Discussion

Tumor growth and metastatic development require coordinated regulation of many cellular pathways. Often, these pathways exist in a balance, whereby tumor cells are shifted between growth and metastasis by precise molecular alterations (2). Here, we show that the promoter for TMEM16A is hypermethylated in metastatic tissues, and that this change in methylation is correlated with a decrease in TMEM16A mRNA and protein expression. This decrease in TMEM16A expression drives the cell toward a mesenchymal cell morphology providing enhanced migratory and metastatic capabilities (18). In addition, reduction in TMEM16A led to the formation of smaller tumors in xenograft models, while increasing metastatic development (Fig. 2). Considering this, we infer that SCCHN tumors expressing high levels of TMEM16A during their initial formation have a proliferative advantage, and during the course of metastatic progression TMEM16A is epigenetically downregulated.

(Continued.) D, hypermethylation of the TMEM16A promoter was observed in nodal metastatic tissue for each of the pairs examined. E, in addition, there was a subsequent decrease in the TMEM16A mRNA expression normalized to the expression in the paired tumor sample. The two samples had an identical decrease, which is represented by the bold line. F–H, the same primary and LN metastatic tissue demonstrated an overall decrease in E-cadherin mRNA expression, and an increase in vimentin and Snail mRNA expression for the primary tissue compared with the LN Met demonstrating an EMT. I, a diagram summarizing our results and TMEM16A’s role in EMT and metastatic progression is shown.
Our proposed model expands on the recently suggested “Grow” or “Go” hypothesis for tumors that activate the Ras–ERK pathway (2). In this transformative model, during periods of growth, the Ras–ERK pathway becomes upregulated to promote proliferation and cell survival, as we have previously observed with increased TMEM16A expression (6). During the transition to the “Go” state, the Ras–ERK pathway can be downregulated to slow cell division while allowing migration and invasion to proceed. Our results serve as key evidence in support of this “Grow” or “Go” hypothesis, and highlight the importance of considering tumor growth and metastasis as independent phenomenon during the design of clinical strategies for advanced-stage disease.

We posit that for a tumor cell to successfully metastasize, the cell must switch from the “Grow” morphology to its “Go” morphology. This transition requires highly coordinated regulation of gene expression, causing the cell to alter its cytoskeletal arrangements leading to mesenchymal characteristics, increased motility, and subsequent metastasis. Inferred from our data, altering TMEM16A promoter methylation epigenetically is likely sufficient for a tumor cell to dynamically regulate its morphology and growth characteristics during tumor progression.

In addition, the acquisition of a mesenchymal phenotype, which we observed to be induced upon stable TMEM16A knockdown, is known to facilitate motility and dissemination of tumor cells, and to be associated with alterations in gene methylation status (18). Specifically, in breast cancer, increased hypermethylation leads to loss of E-cadherin expression in the primary tumor resulting in disruption of cell–cell adhesion, and promotion of motility and invasion. Through increased hypermethylation, the tumor cells can decrease TMEM16A expression and concomitantly drive a decrease in E-cadherin expression and an increase in vimentin expression to promote EMT and metastasis. Interestingly, in distant metastatic foci outside of the lymphatic system, a reverse process has been observed in which the tumor cells undergo a redifferentiation process of MET to allow for the resurgence of tumor growth within the new environment (23). This process again uses promoter demethylation to endogenously induce E-cadherin expression resurgence, and can be influenced by the tumor microenvironment (23, 24). Taken together, our data evoke an intriguing possibility, whereby an environmental sensor present within the cell, possibly TMEM16A, can induce epigenetic changes through alterations in critical gene promoter activity. These changes can subsequently lead to altered differentiation during the complex transition processes of metastasis. Recent data (Simon and colleagues) suggest that the antiproliferative effects of TMEM16A knockdown are more pronounced in vivo, suggesting that TMEM16A may serve to transduce signaling events between the tumor cell and the microenvironment (25).

We believe that TMEM16A protein expression plays a dynamic role in tumor formation and progression. As a multi-transmembrane domain Ca2+–activated Cl− channel, it is uniquely positioned to serve as a tool for sensing the extracellular milieu and regulating cell proliferation through the Ras–Raf–ERK signaling pathway by promoting E-cadherin expression and modulating the actin cytoskeleton via interactions with S970 and Radixin, and cell size by increasing overall volume and area. Almaca and colleagues previously reported the S970 residue of TMEM16A to be important for cell swelling induced by chloride fluxes (11). Overexpression of wild-type TMEM16A, but not the TMEM16A S970A mutant, led to an increase in overall cell size (Fig. 5). In light of the recent report suggesting that TMEM16A can associate with the ERM proteins to facilitate interactions between the cell membrane and the actin cytoskeleton, we hypothesized that the S970 mediated the TMEM16A–ERM interaction (22). In our proteomics evaluation of cytoskeletal and motility-associated proteins, we found Radixin to increase in expression with TMEM16A overexpression and decrease with shRNA knockdown. We further demonstrated that the S970 residue of TMEM16A is required for TMEM16A’s association with Radixin, and that this residue is required for the effects on cell morphology and epithelial characteristics associated with increased TMEM16A expression, independent on its ability to increase cell proliferation. These findings provide additional support for our hypothesis that TMEM16A is well positioned to influence cytoskeletal dynamics, changes in the cell shape, and modulate tumor cell motility, independently of its effects on tumor cell proliferation.

These results could seem contradictory when considering previous reports that demonstrate TMEM16A knockdown causes in fact a decrease in motility (26). We believe, however, that differences between our results and previous reports may arise from differences in experimental techniques; specifically, transient knockdown with siRNA against TMEM16A used during wound-healing assays in vitro, and/or by the potential for cell line variations between the studies and the lack of in vivo data (13, 27). By using a transient knockdown of TMEM16A, these authors may not have efficiently disseminated TMEM16A’s effects on growth and motility. We have previously reported that reduction in TMEM16A results in a decrease in proliferation (6) exemplifying the importance to conduct motility experiments in stably expressing cell lines to avoid potential cytotoxic effects of TMEM16A siRNA (Fig. 2). In our experimental design, we have considered these potential pitfalls and conducted all experiments in stably overexpressing or knockdown cells lines. More importantly, we established our key conclusions in multiple in vitro and in vivo settings, and obtained primary and metastatic tissue samples from patients with SCCCHN directly confirming our experimental findings (Figs. 1 and 6).

It should be noted that some authors have reported that early metastatic lesions demonstrate characteristics of MET, which is in distinction to the EMT phenotype observed in our experiments (14, 15). Chao and colleagues reported that in distant metastases E-cadherin is frequently upregulated (suggesting MET); however, LN metastases do not demonstrate this phenotype (24). These data suggest that...
TMEM16A, a Switch between Tumor Growth and Metastasis

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Disclaimer
The contents of this article do not represent the views of the Department of Veterans Affairs, or the United States Government.

Authors' Contributions
Conception and design: D.J. Shiwarski, A. Bill, J.N. Myers, L.A. Gaither, U. Duvvuri
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): D.J. Shiwarski, C. Shao, J. Kim, D. Xiao, C.A. Bertrand, R.S. Sreehala, D. Sano, P. Ha, M.A. Puthenveedu, U. Duvvuri
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): D.J. Shiwarski, C. Shao, A. Bill, D. Xiao, C.A. Bertrand, R.S. Sreehala, D. Sano, P. Ha, L.A. Gaither, U. Duvvuri
Writing, review, and/or revision of the manuscript: D.J. Shiwarski, C. Shao, A. Bill, D. Xiao, D. Sano, J.N. Myers, P. Ha, J. Grandis, L.A. Gaither, M. A. Puthenveedu, U. Duvvuri
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): D.J. Shiwarski, M.A. Puthenveedu, U. Duvvuri
Study supervision: C.A. Bertrand, U. Duvvuri

Acknowledgments
The authors acknowledge the use of the lentiviral core facilities supported by the University of Pittsburgh Cancer Institute Cancer Center Support Grant P01CA047904.

Grant Support
This work was supported in part by the Head and Neck Cancer SPORE grant (P50-CA097190, to J. Grandis), through a Career Development Award and a Pilot Project grant from the Department of Veterans Affairs Biomedical Laboratory Science Research and Development R&D (to U. Duvvuri), the PNC Foundation, the University of Pittsburgh Competitive Medical Research Fund, and start-up funds from the Department of Otolaryngology, University of Pittsburgh School of Medicine (to U. Duvvuri).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received February 12, 2014; revised April 19, 2014; accepted June 5, 2014; published OnlineFirst June 11, 2014.

References

Clinical Cancer Research

To "Grow" or "Go": TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN

Daniel J. Shiwarski, Chunbo Shao, Anke Bill, et al.


Updated version Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-14-0363

Supplementary Material Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2014/06/11/1078-0432.CCR-14-0363.DC1

Cited articles This article cites 27 articles, 10 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/20/17/4673.full#ref-list-1

Citing articles This article has been cited by 8 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/20/17/4673.full#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/20/17/4673.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.